Genentech

JPM Week: Genentech CEO says partnerships, speedier trials among pandemic's 'silver linings'
JPM Week: Genentech CEO says partnerships, speedier trials among pandemic's 'silver linings'
Fierce Pharma
Genentech
JPMHC 2021
partnerships
Flag link:
Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling
Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling
Fierce Biotech
Atalanta Therapeutics
Biogen
Genentech
F-Prime
neurodegenerative disease
Flag link:
Genentech Launches $1B+ RNA Collaboration with Ribometrix
Genentech Launches $1B+ RNA Collaboration with Ribometrix
Genetic Engineering News
Genentech
Roche
Ribometrix
small molecule drugs
drug discovery
R&D
Flag link:
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Genentech pays Relay $75M for cancer drug, plans KRAS combo
Fierce Biotech
Genentech
Relay Therapeutics
Roche
KRAS inhibitors
Flag link:
A Genentech-partnered Vijay Pande favorite nabs $52M to advance an AI pipeline
A Genentech-partnered Vijay Pande favorite nabs $52M to advance an AI pipeline
Endpoints
Genesis
artificial intelligence
Genentech
Flag link:
Growing Opportunities – The Latest Job Expansions in the Life Sciences Industry
Growing Opportunities – The Latest Job Expansions in the Life Sciences Industry
BioSpace
hirings
Genentech
Revance Therapeutics
Novavax
Cold Chain Technologies
August Bioservices
Halda
Flag link:
FDA approves Roche’s Xofluza to prevent flu spreading in families
FDA approves Roche’s Xofluza to prevent flu spreading in families
Pharmaforum
FDA
Xofluza
Roche
Genentech
Flu
Flag link:
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Novartis
Genentech
Lucentis
biosimilars
Samsung Bioepis
Biogen
FDA
Flag link:
Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics
Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics
Endpoints
Roche
Genentech
artificial intelligence
drug development
drug discovery
Genesis Therapeutics
Flag link:
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies
Pharmaforum
Roche
Genentech
AbbVie
Venclexta
AML
clinical trials
FDA
Flag link:
Months after retiring from Genentech, Michael Varney brings his drug hunting eye to Frazier
Months after retiring from Genentech, Michael Varney brings his drug hunting eye to Frazier
Endpoints
Michael Varney
Genentech
R&D
Frazier Healthcare
Flag link:
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Fierce Biotech
Genentech
Vaccibody
cancer
vaccines
Roche
cancer vaccines
Flag link:
'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups
'Rigged' healthcare? Genentech survey reveals unfair treatment among marginalized groups
Motley Fool
Roche
Genentech
racial diversity
racial discrimination
Flag link:
Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab
Hits, but mostly misses for Roche’s 4 late-stage trials of GI drug hopeful etrolizumab
Fierce Biotech
Roche
Genentech
etrolizumab
clinical trials
ulcerative colitis
Flag link:
Genentech to eliminate 474 positions
Genentech to eliminate 474 positions
Beckers Hospital Review
Genentech
layoffs
COVID-19
Flag link:
Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer
Genentech's Tecentriq-Avastin Combo Fails to Hit Primary Endpoint in Ovarian Cancer
BioSpace
Genentech
Roche
clinical trials
Tecentriq
ovarian cancer
Flag link:
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Flag link:
Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study
Roche's Checkpoint Inhibitor Hits the Mark in Early Triple-Negative Breast Cancer Study
BioSpace
Roche
Genentech
Tecentriq
triple negative breast cancer
clinical trials
Celgene
Abraxane
Flag link:
Denali scoots past a setback with barely a scratch, quickly calling up a backup Alzheimer’s player on the bench
Denali scoots past a setback with barely a scratch, quickly calling up a backup Alzheimer’s player on the bench
Endpoints
Denali Therapeutics
Genentech
DNL747
Flag link:
Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD
Genentech’s Phase III Trial Yields Positive Results and Hope for Patients with Wet AMD
BioSpace
Genentech
clinical trials
wet age-related macular degeneration
ranibizumab
Flag link:

Pages